proven *Legionella* infection due to serogroups other than 1 did not show a serological response to the serogroup 1 antigen. These cases could well have been missed if polyvalent pools of *Legionella* antigens other than serogroup 1 had not been used.

RJ FALLON

WH ABRAHAM

Department of Laboratory Medicine,
Ruchill Hospital,
Bilsland Drive, Glasgow G20 9NB

References

- ¹ Taylor AG, Harrison TG. *Lancet* 1981;ii:591.
- ² Fallon RJ, Abraham WH. Legionnaires' disease. *Lancet* 1978;ii:1318.
- ³ Fallon RJ, Abraham WH. Polyvalent heat-killed antigen for the diagnosis of infection with *Legionella pneumophila*. *J Clin Pathol* 1982;35:434-8.

Aluminium-induced dialysis osteomalacia

We were interested to read the paper by Buchanan *et al* in your issue of December 1981 concerning the use of Aluminon (aurine tricarboxylic acid) to stain aluminium in the bone of haemodialysis patients.¹

Over the past few years we have successfully applied this technique (together with other standard methods for staining aluminium such as solochrome azurine and naphthochrome green) to demonstrate aluminium in formalin or alcohol fixed undecalcified bone sections after embedding in our standard resin (Bondglass, Polymaster 1209 AC).

The stains are positive in experimentally-induced peritoneal aluminium granulomata, in the bones of rats given aluminium chloride and in the bones of patients with chronic renal failure dialysed with water containing aluminium and seem to provide a reliable indication of the presence and localisation of aluminium in bone. Thus these patients and the experimental animals have raised serum aluminium concentrations, increased amounts of aluminium in bone as estimated by neutron activation analysis and recently it has been confirmed by microprobe analysis that the aluminium is located in the region of the mineralisation front^{2,3} precisely where the positive staining reaction occurs.

In our experience the staining reaction appears mainly in the site of the mineralisation front as a narrow finely granular line at the interface between mineralised bone and osteoid and just spreading on to the osteoid itself corresponding to the position

and appearance of a toluidine blue stained normal mineralisation front. In addition there is frequently a narrow line of positive staining at the bone surface not covered by osteoid or in cement lines. In some patients treated for years with a dialysate containing aluminium cement lines giving a positive reaction may be seen deep in bony trabeculae and in cortical bone. Less frequently the stain is positive in finely granular patches in osteoid where there are attempts at abnormal mineralisation. In the past we have noted this type of positive reaction in the osteoid and surrounding osteocyte lacunae particularly in the bones of patients with aluminium-induced osteomalacia who had been treated with 1 α -hydroxy vitamin D3 and phosphate supplements before the cause of the osteomalacia was fully appreciated.

The locations described probably represent the true sites of accumulation of aluminium in bone. Incorporation of aluminium in the mineralisation front with subsequent interference with normal mineralisation would provide a convenient explanation for the development of osteomalacia in the dialysis patients and aluminium-treated experimental animals. It could be argued however that the aluminium is located elsewhere in the bone or marrow in life and diffuses during the processing of the bone to become secondarily "fixed" in the region of the mineralisation front. Studies of rapidly frozen fresh bone by microprobe analysis will be needed to resolve this problem.

In some haemodialysis patients initially without osteomalacia we have noted the accumulation of aluminium in bone and development of osteomalacia in serial iliac bone biopsies and any osteitis fibrosa initially present tends to resolve. However there are some patients with increased amounts of bone aluminium, as judged by the staining reaction and confirmed by neutron activation analysis, who do not develop osteomalacia. These patients tend to be amongst those with progressively severe hyperparathyroidism and osteitis fibrosa and interestingly we have observed that osteomalacia may develop in some of these patients following parathyroidectomy. It seems that severe degrees of hyperparathyroidism may provide some protection against the adverse effect of aluminium on bone mineralisation.

Since the importance of aluminium in inducing osteomalacia was appreciated the disease has been eliminated in most centres by using appropriate water treatment (deionisation, reverse osmosis). In Newcas-

tle, which was formerly a centre with crippling dialysis osteomalacia, no new cases have occurred in recent years. We still see occasional referred examples from centres elsewhere and wish to stress the value of using these simple staining techniques when examining iliac bone biopsies from dialysis patients.

This type of osteomalacia does not heal following the use of the newer vitamin D3 metabolites such as 1 α -hydroxy vitamin D3 or 1,25 dihydroxy vitamin D3 and troublesome hypercalcaemia with soft tissue calcification often ensues.⁴ The aluminium stain provides a simple means of distinguishing this particular group of patients.

The main source for the aluminium is the water used for the preparation of the dialysate, particularly in those regions where aluminium is added to the water supply to flocculate colloidal suspensions. However increased serum aluminium and deposition of stainable aluminium in bone can result from the use of oral aluminium-containing phosphate binders even in predialysis patients with chronic renal failure. In addition we have studied bone biopsies from several patients who developed multiple fractures after treatment by a closed loop haemofiltration system (Redy cartridge) in which there has been osteomalacia and characteristic deposition of aluminium. In such instances the aluminium is released from the cartridge.

Dialysis encephalopathy is another complication of aluminium intoxication and may accompany dialysis osteomalacia. The chelating agent desferrioxamine has been used to treat this condition and with some success.⁵ Recently we have observed healing of aluminium-induced dialysis osteomalacia in serial iliac bone biopsies from a patient treated with desferrioxamine and the amount of stainable aluminium in the bone was apparently reduced. With the exception of renal transplantation, it has been our experience that other forms of treatment are usually ineffective in this type of osteomalacia.

Finally, it is worth mentioning that the aurine tricarboxylic acid stain is reliable and reproducible provided one ignores false-positive reactions which may occasionally occur at the fragmented and fibrillated ends of traumatised trabeculae or cortical bone at the margins of the bone biopsy.

HA ELLIS

WHB MAWHINNE

Department of Pathology
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LQ

J Clin Pathol, first published as 10.1136/jcp.35.7.792 on 1 July 1982. Downloaded from <http://jcp.bmj.com/> April 2, 2023 by guest. Protected by copyright.

References

- ¹ Buchanan MRC, Ihle BU, Dunn MC. Haemodialysis related osteomalacia: a staining method to demonstrate aluminium. *J Clin Pathol* 1981;**34**:1352-4.
- ² Boyce BF, Elder HY, Fell GS, *et al.* Quantitation and localisation of aluminium in human cancellous bone in renal osteodystrophy. *Scann Electron Microsc* 1981;**3**:329-37.
- ³ Cournot-Witmer G, Zingraff J, Plachot JJ, *et al.* Aluminium localization in bone from hemodialyzed patients: relationship to matrix mineralization. *Kidney Int* 1981;**20**:375-85.
- ⁴ Ellis HA, Pierides AM, Feest TG, Ward MK, Kerr DNS. Histopathology of renal osteodystrophy with particular reference to the effects of 1 α -hydroxy vitamin D3 in patients treated by long-term haemodialysis. *Clin Endocrinol (Oxf)* 1977;**7**, suppl:31-8.
- ⁵ Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. *Lancet* 1980;ii:692-3.